Navigation Links
Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer

Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.

The study appeared in the Feb. 13 online issue of Oncogene.

The IKBKE gene is part of a family of enzyme complexes involved in increasing cellular inflammation. IKBKE overexpression has been associated with breast and prostate cancers. However, it had not been linked to environmental carcinogen, such as tobacco smoke, until now.

Tobacco smoke is the strongest documented initiator and promoter of lung cancer. The traditional model holds that tobacco components promote carcinogenesis through a process that leads to DNA damage.

Recent studies have shown that tobacco smoke can also promote lung cancer through changes in the pathways that regulate cell proliferation and survival. This study explored identifying and understanding one of the signaling pathways in order to find potential drug targets to treat non-small cell lung cancer.

In this study, IKBKE was found to be induced by two tobacco carcinogens: nicotine and a nicotine-derived nitrosamine ketone found in tobacco smoke. Their findings suggest that IKBKE is a key molecule related to tobacco-induced lung cancer.

"Since IKBKE kinase is induced by tobacco, small molecular inhibitors of IKBKE could have a therapeutic drug potential for lung cancer," explained lead author Jin Q. Cheng, Ph.D., M.D., senior member of the Molecular Oncology Department at Moffitt.

Current treatments for non-small cell lung cancer include surgery, radiotherapy and chemotherapy. However, patients eventually develop resistance to treatment. There is a great need to better understand the molecular mechanism of resistance and develop new gene-targeted therapies that can circumvent resistance, said the authors.

In this study, the researchers also reported for the first time that IKBKE is a target of STAT3, a transcription factor that plays a key role in many cellular processes, such as cell growth and programmed cell death.

According to the researchers, STAT3 is frequently activated in various types of human cancers and, when activated, STAT3 increases IKBKE overexpression and protein levels. In non-small cell lung cancer, nicotine-induced IKBKE depends on STAT3.

The authors noted that the activation stage of STAT3 represents an attractive therapeutic potential because IKBKE is a STAT3 target. While IKBKE induces chemotherapy resistance, knocking down IKBKE sensitizes cancer cells to chemotherapy and reduces cancer cell survival.

"Since the IKBKE kinase overexpression is induced by tobacco smoke and IKBKE levels increase in response to nicotine and nicotine-derived nitrosamine ketone, this evidence can be potentially used to develop a non-small cell lung cancer intervention strategy that targets IKBKE," concluded Cheng.


Contact: Kim Polacek
H. Lee Moffitt Cancer Center & Research Institute

Related medicine news :

1. Moffitt Cancer Center researchers develop automated breast density test linked to cancer risk
2. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
3. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
4. Moffitt study shows smoking cessation more successful for cancer patients who quit before surgery
5. Hispanics leery of health care providers, often avoid cancer screenings, Moffitt study shows
6. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
9. Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
10. Moffitt researchers identify unique immune gene signature across thousands of patients solid tumors
11. Moffitt Cancer Center researcher receives $2.1 million grant from NCI for answering Provocative Question
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of the ... stellar workplace culture with the company’s Cincinnati office being named a finalist among ... was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati Best ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health ... launches new Wimbledon Athletics Facebook page to educate the public, parents ... cardiac abnormalities. About 2,000 people under the age of 25 die from sudden ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a ... tracking systems. The new app features a more intuitive SleepScore™ that rates sleep quality ... you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
Breaking Medicine Technology: